Skip to content

美拉基因治疗

US · MGTX #3220 按市值排名 上市于 2018
9.28 -0.61 -6.17%
实时 - 追踪5344个代码 - 心跳于479秒前 · 2026-10-16 20:02

估值 各估值倍数与自身5年区间的对比

市净率 4.82 高于历史水平 第72百分位
5年平均 8.87 · 在Biotechnology中排名第376/513
市盈率 12.44 高于历史水平 第97百分位
5年平均 -3.81 · 前瞻 -5.51 · 在Biotechnology中排名第37/73
市销率 2.61 低于历史水平 第0百分位
5年平均 25.30 · 前瞻 29.34 · 在Biotechnology中排名第57/387

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
美拉基因治疗 (MGTX) 891.28M 10.67 4.13 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★☆☆☆ 合理价值9.51 经济护城河None 不确定性High

当前股价低于晨星合理价值估算2.4%。

合理价值

MeiraGTx Holdings PLC earns a 2-star quantitative star rating, reflecting our opinion that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 14% premium over our quantitative fair value estimate of $9.51 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's valuation metrics weaken our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 21.2% falls in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

On a different note, the company's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 11.8%, a core component of profitability, falls in the top 20% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:02:13 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

美拉基因治疗 讨论区 0 条评论

发表评论